Electric Stimulation Home Use(CGM MEPC_2401) for Improving Blood Circulation

NCT07446088 | Recruiting

• 1 other identifier: CG03-KR25BLC101
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a single-center, open-label, exploratory clinical trial to evaluate the safety and efficacy of a statics electricity generator for improving blood circulation.

Conditions

Improving Blood Circulation; Blood Circulation

Keywords

blood circulation

Outcome Measures

Primary Outcomes (1)

• Change and percent change in blood flow of the dorsal metacarpal vein

  Change and percent change in blood flow of the dorsal metacarpal vein from baseline to immediately after a 30-minute application of the investigational device

  from baseline to immediately after a 30-minute application of the investigational device

Secondary Outcomes (3)

• Change and percent change in capillary diameter assessed by capillary microscopy

  from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)

• Change and percent change in oxygen saturation (SpO₂)

  from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)

• Change and percent change in blood zeta potential, cellular ATP levels, nitric oxide, membrane potential, and matrix metalloproteinases

  from baseline to immediately after a 30-minute application of the investigational device (total duration: 30 minutes)

Study Arms (1)

CGM MEPC-2401

EXPERIMENTAL

Device: CERAGEM CELLTRON CIRCULATION CHAIR (CGM MEPC-2401)

Interventions

CERAGEM CELLTRON CIRCULATION CHAIR (CGM MEPC-2401) DEVICE

Improving blood circulation device (Ceragem Celltron Circulation Chair)

CGM MEPC-2401

Eligibility Criteria

• Age: 19 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults aged between 19 and 65 years
• Individuals with a BMI of 30.0 kg/m² or less
• Individuals without abnormal findings on hematology tests (CBC)

You may not qualify if:

• Patients with uncontrolled hypertension despite medication (defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg measured at rest)
• Patients with medical conditions requiring the use of assistive devices (e.g., pacemaker, artificial joint, stent, prosthesis, etc.)
• Patients with seizure disorders or a history of loss of consciousness (e.g., epilepsy, acute febrile convulsions such as those associated with severe fever, etc.), or those at high risk of electric shock due to such conditions
• Patients with ventricular arrhythmias (e.g., ventricular tachycardia, history of coronary artery bypass surgery, etc.) and patients with neurological disorders (e.g., diabetic neuropathy, etc.)

Sponsors & Collaborators

• Ceragem Clinical Inc.: lead

Study Sites (1)

Wonju Severance Christian Hospital

Wŏnju, South Korea

RECRUITING

Study Officials

• Kwang Yong Shim, MD

  Wonju Severance Christian Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Myeongbae Shin, Researcher

CONTACT

82-10-4373-2808; mbshin94@ceragem.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 2, 2026
• First Posted: March 3, 2026
• Study Start: December 1, 2025
• Primary Completion: June 30, 2026
• Study Completion: June 30, 2026
• Last Updated: March 3, 2026

Record last verified: 2026-02

Locations

KR (1)